Eli Lilly and Company has received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO) for its Alzheimer's treatment, donanemab. The approval allows for the use of the drug in adults who are in the early symptomatic stages of the disease, including those with mild cognitive impairment and mild dementia. Donanemab is a disease-modifying therapy that targets the amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. By targeting these plaques, the intravenous infusion treatment aims to slow the rate of cognitive decline in patients. This regulatory green light marks a significant step for Eli Lilly in expanding the global reach of its neuroscience portfolio and provides a new therapeutic option for the growing number of Alzheimer's patients in India. The company highlighted its commitment to addressing the needs of those living with the disease in the country.